Posted on Mar 19, 2015 11:17:00 AM by Leslie Wooldridge, GNP-BC, CUNP, BCIA-PMD

Antimuscarinic Medications and PTNS

How to Approach Antimuscarinic Medications During PTNS Treatment

There are a couple of scenarios that resonate with patients who are refractory to conventional treatments for Man with drugsOAB.  

There is that patient for whom you have done absolutely everything. They are compliant with behavioral interventions and have tried a multitude of antimuscarinic medications. Somehow they are just not where they want to be.  PTNS would be the next obvious option.  

Option 1

My first strategy is to keep them on the last antimuscarinic being used until the 5th treatment. Then I wean them off their medication. My strategy is to achieve that of a placebo effect. We are weaning them off daily doses while they think they are getting adequate doses. When they are completely off the drugs and they are still doing great, they are happy. In my experience, I have found that the effect of just stopping animuscarinics too often presents with a show of panic for the patient. We always want to invest confidence in our patients that we will not let them fall backwards.

That brings me to my next scenario. So you have weaned your patient off his/her anitmuscarinic medication.  Most of the time they will continue to improve, get even better and be very happy patients. Then, there are those who will fall back into where they were when they started PTNS. Better, but not great.  

Option 2

Restart their medication. Keep in mind there are 20% of our patients who are refractory to any and all treatments. There isn’t data on outcomes of combining these treatments in the published literature. However, in our clinic, we do it when we need to and have positive results. It works. Insurance pays. Unfortunately there are those patients who need more than one approach to reach their goals. We have the tools. Let's use them!

Urgent PC for OAB

This blog post reflects the opinions and experience of Leslie Wooldridge, a long-standing user of the Urgent PC Neuromodulation System, and was produced under a paid consulting agreement with Cogentix Medical.

Urgent PC is indicated for the treatment of Overactive Bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Treatment with Urgent PC is contraindicated for patients with pacemakers or implantable defibrillators, patients prone to excessive bleeding, patients with nerve damage that could impact either percutaneous tibial nerve or pelvic floor function or patients who are pregnant or planning to become pregnant during the duration of the treatment. Most patients don't experience side-effects. If side-effects occur, they are typically temporary and include mild pain and skin inflammation at or near the stimulation site. Caution: Federal law (USA) restricts this device to sale by or on the order of a physician. For complete instructions for use, storage, warnings, indications, contraindications, precautions, adverse reactions and disclaimer of warranties, please refer to the insert accompanying each product or online at Models are for illustrative purposes only. Urgent is a registered trademark of Cogentix Medical © 2015 Cogentix Medical. All rights reserved. 

Leslie Wooldridge, GNP-BC, CUNP, BCIA-PMD
Leslie Saltzstein Wooldridge, GNP-BC, CUNP, BCIA-PMD, is Director of the Adult Bladder Control Center, Mercy Health Partners, Muskegon, Michigan USA. Ms. Wooldridge received a Master of Science degree in nursing administration, critical care nursing and postgraduate certification as a Geriatric Nurse Practitioner from Marquette University, Milwaukee, Wisconsin. In 2015, she was honored with the Women’s Health Foundation Activist Award. She is also the recipient of the 2009 National Association for Continence Rodney J. Appell Continence Champion Award. Ms. Wooldridge has published in multiple refereed journals. She authored the Genitourinary chapter in The Nurse Practitioner in Long Term Care: Guidelines for Clinical Practice (2007). She has lectured throughout the United States on geriatrics, urology and clinical practice.
Return To Blog